Imaging and Samples for Colon Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new methods to diagnose colon cancer and assess its likelihood of spreading to organs like the liver. The study involves procedures such as colectomy or hepatectomy, which remove parts of the colon or liver. Suitable participants include those undergoing surgery for stage I-IV colon cancer or to remove large, potentially non-cancerous colon growths. The trial focuses on individuals having surgery as part of their regular treatment plan. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could enhance future diagnostic methods.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications, but it does exclude those who have received experimental therapies for colon cancer. It also mentions that medications increasing bleeding risk after a liver biopsy may be a concern, so it's best to discuss your specific medications with the trial team.
What prior data suggests that these diagnostic methods are safe for patients?
Research has shown that surgeries like colectomy and hepatectomy, which involve removing parts of the colon or liver, are generally safe. Studies indicate that liver surgeries for cancer patients are often well-tolerated. One study found that performing liver and colon surgeries simultaneously is safe and yields good results. Most patients recover from these surgeries without major complications, and many live for several years afterward.
Another study found that about 30% of patients who underwent liver surgery for colon cancer lived for five years or more, with many remaining cancer-free. Even older patients, over 70, had a survival rate of up to 44% five years after surgery. These findings suggest that the surgeries are usually safe and may effectively treat cancer.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to enhance how we treat colon cancer and liver tumors by using advanced imaging, blood, and tissue analysis to guide surgical decisions. Unlike current treatment protocols that largely rely on standard surgical and chemotherapy approaches, this study investigates how personalized data can optimize the timing and type of surgery, such as colectomy or hepatectomy, based on the tumor's specific characteristics. This approach could lead to more tailored treatments, potentially improving outcomes and minimizing unnecessary interventions. By integrating cutting-edge diagnostic tools, researchers hope to pave the way for more precise and effective cancer treatments in the future.
What evidence suggests that this trial's methods could be effective for diagnosing and predicting the spread of colon cancer?
This trial will compare different surgical approaches for colon cancer, including colectomy or hepatectomy, based on the stage and resectability of hepatic metastases. Research has shown that surgery to remove parts of the colon (colectomy) or liver (hepatectomy) can effectively treat colon cancer and related liver tumors. For patients undergoing liver surgery for cancer that has spread from the colon to the liver, the 5-year survival rate is encouraging, indicating that surgery can sometimes cure the disease. In some cases, about 24% of patients live for 10 years after liver surgery, with around 20% achieving a cure. Patients with a single liver tumor have a 5-year survival rate without disease recurrence, ranging from 30% to 38.9%. These findings suggest that surgery can significantly improve long-term survival and may even cure the disease.36789
Who Is on the Research Team?
Michael D'Angelica
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo imaging and laboratory tests to monitor liver pre-metastatic niche and guide treatment of colon cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- blood draws
- colectomy or hepatectomy
- Fibroscan test
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Weill Medical College of Cornell University
Collaborator
Citations
Actual 10-year survival following hepatic resection of ...
Actual 10-year survival after resection of CRLM is 24% with an observed 20% cure rate. Patients with both high CRS and EHD have an estimated probability of cure ...
The oncologic outcome and prognostic factors for solitary ...
Patients with multiple metastases achieve a 5-year DFS rate of 18.1%, whereas those with solitary metastasis reach 30.0% to 38.9% [2], [6], [7]. Multiple risk ...
Safety and long-term prognosis of simultaneous versus staged ...
Simultaneous resection is safe and effective for SCLM patients. The long-term prognosis is equivalent to that of the traditional staged resection.
Short-term Quality-of-Life Outcomes Following ...
Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy.
Five‐year survival post hepatectomy for colorectal liver ...
Surgical resection is a curative treatment for long-term survival in patients with colorectal liver metastases (CRLM), with a 5-year survival ...
Outcomes of liver resection in patients with colorectal ...
Approximately 20% of liver metastases are found to be resectable. The objective of this study was to evaluate short-term outcomes of patients ...
Outcomes of Simultaneous Major Liver Resection and ...
Colorectal cancer with synchronous liver metastases is found in approximately 20–25 % of patients at the time of diagnosis. Approximately 80–90 % of patients ...
Surgical resection of hepatic metastases from colorectal ...
Approximately 30% of patients remained alive 5 years after resection and around two-thirds of these are disease free. The quality of the ...
Long‐term outcomes after hepatic resection for colorectal ...
For elderly patients, mostly defined as being >70 years old at hepatic resection, 5-year survival rates varying between 21% and 44% have been ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.